Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIO NASDAQ:ETON NASDAQ:IRON NASDAQ:TVTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$40.89+1.0%$37.51$23.42▼$62.58$2.35B0.83624,202 shs401,602 shsETONEton Pharmaceuticals$20.73+4.0%$17.58$6.37▼$23.00$534.47M1.16337,536 shs344,614 shsIRONDisc Medicine$69.28+2.2%$61.04$30.82▼$69.87$2.36B0.8380,936 shs360,328 shsTVTXTravere Therapeutics$26.13+6.0%$20.40$12.91▼$28.69$2.20B0.832.69 million shs2.33 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals0.00%+4.03%+12.47%+15.02%-2.00%ETONEton Pharmaceuticals0.00%-6.30%+12.79%+38.50%+184.71%IRONDisc Medicine0.00%+3.40%+11.55%+26.98%+35.75%TVTXTravere Therapeutics0.00%-2.61%+13.86%+68.77%+61.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$40.89+1.0%$37.51$23.42▼$62.58$2.35B0.83624,202 shs401,602 shsETONEton Pharmaceuticals$20.73+4.0%$17.58$6.37▼$23.00$534.47M1.16337,536 shs344,614 shsIRONDisc Medicine$69.28+2.2%$61.04$30.82▼$69.87$2.36B0.8380,936 shs360,328 shsTVTXTravere Therapeutics$26.13+6.0%$20.40$12.91▼$28.69$2.20B0.832.69 million shs2.33 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals0.00%+4.03%+12.47%+15.02%-2.00%ETONEton Pharmaceuticals0.00%-6.30%+12.79%+38.50%+184.71%IRONDisc Medicine0.00%+3.40%+11.55%+26.98%+35.75%TVTXTravere Therapeutics0.00%-2.61%+13.86%+68.77%+61.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.86Moderate Buy$56.0036.95% UpsideETONEton Pharmaceuticals 2.50Moderate Buy$29.6743.11% UpsideIRONDisc Medicine 2.92Moderate Buy$98.3041.89% UpsideTVTXTravere Therapeutics 2.75Moderate Buy$34.2030.88% UpsideCurrent Analyst Ratings BreakdownLatest ETON, IRON, AGIO, and TVTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025AGIOAgios PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/27/2025ETONEton PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025IRONDisc MedicineWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025TVTXTravere TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/19/2025TVTXTravere TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.009/12/2025TVTXTravere TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$20.00 ➝ $25.009/11/2025TVTXTravere TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$27.00 ➝ $35.009/10/2025TVTXTravere TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$35.009/10/2025TVTXTravere TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.009/4/2025AGIOAgios PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$56.009/3/2025TVTXTravere TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.00(Data available from 10/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$36.50M65.09N/AN/A$27.02 per share1.51ETONEton Pharmaceuticals$39.01M14.25N/AN/A$0.94 per share22.05IRONDisc MedicineN/AN/AN/AN/A$14.85 per shareN/ATVTXTravere Therapeutics$233.18M9.99N/AN/A$0.76 per share34.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals$673.72M$11.003.72N/AN/A1,590.42%-3.49%-3.23%10/30/2025 (Estimated)ETONEton Pharmaceuticals-$3.82M-$0.16N/A41.46N/A-7.10%-0.73%-0.22%11/11/2025 (Estimated)IRONDisc Medicine-$109.36M-$4.47N/AN/AN/AN/A-26.60%-24.58%11/11/2025 (Estimated)TVTXTravere Therapeutics-$321.55M-$2.04N/AN/AN/A-50.64%-717.68%-30.69%10/30/2025 (Estimated)Latest ETON, IRON, AGIO, and TVTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/30/2025Q3 2025AGIOAgios Pharmaceuticals-$1.94N/AN/AN/A$10.49 millionN/A10/30/2025Q3 2025TVTXTravere Therapeutics-$0.31N/AN/AN/AN/AN/A8/7/2025Q2 2025ETONEton Pharmaceuticals-$0.01-$0.10-$0.09-$0.10$16.71 million$18.93 million8/7/2025Q2 2025IRONDisc Medicine-$1.17-$1.58-$0.41-$1.58N/AN/A8/6/2025Q2 2025TVTXTravere Therapeutics-$0.28-$0.14+$0.14-$0.14$100.18 million$94.84 million7/31/2025Q2 2025AGIOAgios Pharmaceuticals-$1.74-$1.93-$0.19-$1.93$9.46 million$12.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/AIRONDisc MedicineN/AN/AN/AN/AN/ATVTXTravere TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A14.4814.04ETONEton Pharmaceuticals1.141.771.16IRONDisc Medicine0.0532.1132.11TVTXTravere Therapeutics9.502.001.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/AETONEton Pharmaceuticals27.86%IRONDisc Medicine83.70%TVTXTravere TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.93%ETONEton Pharmaceuticals14.89%IRONDisc Medicine3.64%TVTXTravere Therapeutics4.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39058.10 million55.24 millionOptionableETONEton Pharmaceuticals2026.82 million22.83 millionOptionableIRONDisc Medicine3034.77 million33.50 millionNot OptionableTVTXTravere Therapeutics46089.14 million85.52 millionOptionableETON, IRON, AGIO, and TVTX HeadlinesRecent News About These CompaniesTravere Therapeutics (NASDAQ:TVTX) Upgraded at Wall Street ZenOctober 5 at 3:19 AM | americanbankingnews.comTravere Therapeutics (NASDAQ:TVTX) Stock Rating Upgraded by Wall Street ZenOctober 4 at 3:09 AM | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Receives $34.20 Consensus Price Target from BrokeragesOctober 4 at 2:39 AM | americanbankingnews.comTravere Therapeutics price target lowered to $35 from $45 at Evercore ISIOctober 1, 2025 | msn.comTravere Therapeutics (NASDAQ:TVTX) Shares Gap Down - Here's WhyOctober 1, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesOctober 1, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Trading Down 7.6% - What's Next?September 29, 2025 | marketbeat.comCSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA NephropathySeptember 26, 2025 | prnewswire.comTravere Therapeutics (NASDAQ:TVTX) Insider Elizabeth Reed Sells 10,000 SharesSeptember 25, 2025 | insidertrades.comInsider Selling: Travere Therapeutics (NASDAQ:TVTX) Insider Sells 10,000 Shares of StockSeptember 24, 2025 | marketbeat.comTravere Therapeutics, Inc. $TVTX Shares Acquired by Assenagon Asset Management S.A.September 23, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Travere Therapeutics (NASDAQ:TVTX)September 20, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Downgraded by Wall Street Zen to "Hold"September 20, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Price Target Raised to $25.00September 14, 2025 | marketbeat.comTravere Therapeutics, Inc. $TVTX Shares Sold by AQR Capital Management LLCSeptember 14, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Shares Down 4.8% - Should You Sell?September 13, 2025 | marketbeat.comWells Fargo & Company Boosts Travere Therapeutics (NASDAQ:TVTX) Price Target to $35.00September 13, 2025 | marketbeat.comWoodline Partners LP Sells 884,278 Shares of Travere Therapeutics, Inc. $TVTXSeptember 13, 2025 | marketbeat.comTravere Therapeutics: Buy Rating On Back Of Filspari Expansion Towards FSGSSeptember 12, 2025 | seekingalpha.comTravere Therapeutics (NASDAQ:TVTX) Reaches New 1-Year High - Here's What HappenedSeptember 12, 2025 | marketbeat.comTVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDASeptember 11, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025Advance Auto Parts is A Great Risk/Reward Play If EPS DeliversBy Gabriel Osorio-Mazilli | September 22, 2025Take the Money and Run: Strategy Stock Looks Tapped OutBy Gabriel Osorio-Mazilli | September 9, 2025AeroVironment Is a Hot Buy With a Double-Digit UpsideBy Thomas Hughes | September 11, 20253 Small-Cap Stocks to Watch After the Fed’s Rate CutsBy Chris Markoch | September 24, 2025ETON, IRON, AGIO, and TVTX Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$40.89 +0.39 (+0.96%) Closing price 04:00 PM EasternExtended Trading$40.61 -0.28 (-0.69%) As of 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Eton Pharmaceuticals NASDAQ:ETON$20.73 +0.80 (+4.01%) Closing price 04:00 PM EasternExtended Trading$20.84 +0.11 (+0.51%) As of 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Disc Medicine NASDAQ:IRON$69.28 +1.50 (+2.21%) Closing price 04:00 PM EasternExtended Trading$69.19 -0.09 (-0.13%) As of 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.Travere Therapeutics NASDAQ:TVTX$26.13 +1.49 (+6.05%) Closing price 04:00 PM EasternExtended Trading$26.25 +0.12 (+0.46%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Marvell Insiders Buy Shares—Should Investors Follow Suit? Behind D-Wave's Massive Week (And Why Rivals Also Popped) Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? Best Stocks Under $15? 3 Low-Priced Picks With Upside After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
